Search
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitOxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth … Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalcontain an imide group. … [A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.
Categories: P-glycoprotein substratesSiagoside
go.drugbank.com/drugs/DB12351InvestigationalSiagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury. … It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair.
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnHepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form .
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexAmphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalAmphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. … It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted.
Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine ProductCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsCevimeline
go.drugbank.com/drugs/DB00185ApprovedCevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMetaraminol
go.drugbank.com/drugs/DB00610ApprovedIt has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.